Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antivirals - Arisyn Therapeutics

Next Previous
Drug Profile

Research programme: antivirals - Arisyn Therapeutics

Alternative Names: ATI-0409; ATI-0607; ATI-0655; ATI-0810; ATI-5488; PG 301209; PG-301995

Latest Information Update: 12 May 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Arisyn Therapeutics
  • Class Small molecules
  • Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Influenza virus infections

Most Recent Events

  • 15 Sep 2009 Pharmacodynamics data from in vitro studies in Hepatitis C presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 14 May 2009 Pharmacodynamics data from a preclinical trial of ATI 0810 in Hepatitis C released by ImQuest and Arisyn
  • 24 Nov 2008 Compounds from this programme are available for licensing (http://www.arisyn.com)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top